

AWIR 2025 Annual Conference
Elevating Rheumatology Care:
Bridging Evidence-Based Science with Real-World Practice
July 24, 2025-July 26, 2025
Gaylord Palms, Kissimmee, FL & Virtual

Activity Overview

Given the evolving understanding of the onset, severity, and progression of rheumatic diseases, as well as the risk of comorbidities and undertreatment, the AWIR 2025 agenda features disease-specific sessions that offer a deep dive into the assessment, treatment, and management nuances of each condition, with expert-led interpretations of guidelines and evidence.

Target Audience

The primary target audience for the proposed educational sessions as US-based rheumatology prescribing HCPs – including MDs, DOs, NPs, and PAs – who will be attending AWIR's 2025 Annual Conference (virtually or live) on July 24-26, 2025. Because AWIR's Annual Conference is open to the entire AWIR membership and rheumatology community, a secondary audience includes ex-US rheumatology HCPs at AWIR 2025.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

- Identify the key inflammatory pathways involved in rheumatic conditions, their role in disease onset and progression, and treatment potential
- Assess the patient burden of rheumatic diseases, including disease outcomes, patient-reported outcomes, and comorbidities complications
- Evaluate current, new, and emerging treatment options for rheumatic diseases and their comorbidities based on mechanisms of action, indications, and efficacy and safety profiles
- Incorporate patient-specific factors and disease characteristics to personalize treatment decisions for diverse patients with rheumatic diseases
- Apply evidence-based practices for assessing, treating, and managing rheumatic diseases
- Adopt interprofessional strategies to improve communication and coordination between multidisciplinary teams caring for patients with rheumatic diseases
- Analyze real-world challenges and socio-economic barriers to integrating evidence-based and novel treatment approaches

Criteria for Success

Statements of credit will be awarded based on the participant's attendance, completion of pre/post-test, and submission of the activity evaluation/claim credit form at <https://akhinc.formstack.com/forms/250020I>

IMPORTANT: The link will become active on Saturday, July 24th at 12:00 PM EST.

You must participate in the entire activity to receive credit.

If you have questions about this CE activity, please contact AKH Inc at ketrea@akhcme.com.

Please claim your credit by August 26, 2025.
Any credits claimed after this date incur a \$25 late fee.


 JOINTLY ACCREDITED PROVIDER™
 INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Association of Women in Rheumatology. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 15.25 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 15.25 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Physician Associates and Nurse Practitioners

Physician Associates and Nurse Practitioners can claim *AMA PRA Category 1 Credit*™, if appropriate, from organizations accredited by ACCME.

Commercial Support

This activity is supported from an independent medical education grant from Novartis.

Faculty Disclosures

Name	Relationship	Commercial Interest
Joshua Baker, MD, MSCE (faculty)	Consultant	CorEvitas, LLC
Catherine Bakewell, MD, PhMSUS (faculty)	Consultant	AbbVie, Novartis, Johnson & Johnson, BMS, Pfizer, Lilly, UCB
	Speaker	AbbVie
Julius Birnbaum, MD (faculty)	N/A	Nothing to disclose
Cassie Calabrese, DO (faculty)	Consultant	Sanofi, Lilly, Ivivvyd, Musculo
	Speaker	Sanofi
Michele Cerra, MSN, FNP-C (faculty)	Consultant	J & J innovative Medicine, Sanofi, AstraZeneca, Amgen, Eli Lilly
Joyce Chang, MD, MSCE (faculty)	N/A	Nothing to disclose
Katherine Cole, MMS, PA-C (faculty)	N/A	Nothing to disclose
Maria Dall'Era, MD (faculty)	Advisor	GSK, AstraZeneca, Aurinia, Biogen, BMS
	Consultant	Cabaletta, Janssen, Novartis
Sheetal Desai, MD, MEd (faculty)	Consultant, Speaker	AstraZeneca, Aurinia, GSK, Johnson and Johnson
Anita Dhanrajani, MD (faculty)	N/A	Nothing to disclose
Anisha Dua, MD, MPH (faculty)	Consultant	AbbVie, Amgen, Astra Zeneca, GSK, Sanofi, Novartis
	Researcher	Amgen, Novartis
Lih Eder, MD (faculty)	Advisor, Speaker	AbbVie, UCB, BMS, Novartis, Fresenius, Kabi, Eli Lilly, J&J, Pfizer
	Advisor	Moonlake
Candace Feldman, MD, MPH, ScD (faculty)	Consultant	Harvard Pilgrim, BMS Foundation
Jessica Fennell, MD (faculty)	N/A	Nothing to disclose
Marla Guzman, MD (faculty)	N/A	Nothing to disclose
Cindy Johnston, MD (faculty)	Advisor	Specialty Networks
Minna Kohler, M.D., PhMSUS (faculty)	Researcher	Setpoint Medical, Sonoma Therapeutics
	Royalties	Stringer Publications
Philip Mease, MD (faculty)	Consultant	AbbVie, Acelyrin, Amgen, Bristol Meyers Squib, Century,

		Cullinan Biotech, Eli Lilly, Inmagene, Johnson & Johnson, Moonlake, Novartis, Pfizer, Takeda, UCB
	Researcher	AbbVie, Amgen, Bristol Meyers Squib, Eli Lilly, Johnson & Johnson, Moonlake, Novartis, Takeda, UCB
	Speaker	AbbVie, Amgen, Eli Lilly, Johnson & Johnson, UCB
Taraneh Mehrani, MD (faculty)	N/A	Nothing to disclose
Hilary Norton, MD (faculty)	Advisor	Abbvie, SetPoint Medical, Sobi Medical, Janssen
	Researcher	Horizon, Sanofi, Eli Lilly, Acelyrin
	Speaker	Abbvie, Janssen, UCB, Amgen, AstraZeneca
Kathy Perez, MD, MBA, LSCGB (faculty)	N/A	Nothing to disclose
Chris Ritchlin, MD, MPH (faculty)	Consultant	BMS, Takeda, Novartis, Janssen, Moonlake, UCB
Amin Sabet, MD (faculty)	N/A	Nothing to disclose
Rebecca Sadun, MD, PhD (faculty)	N/A	Nothing to disclose
Aubrey Wilson, PA-C (faculty)	N/A	Nothing to disclose
Grace Wright, MD PhD (planner, faculty)	Consultant	Abbvie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, UCB
	Speaker	Novartis, Pfizer, Scipher Medicine
Janeth Vinh, MD, RhMSUS (faculty)	Consultant	Janssen
	Royalties	Springer
Florina Constantinescu, MD (faculty)	N/A	Nothing to disclose
Dorothy Caputo, MA, BSN, RN - President	N/A	Nothing to disclose
Michele Bielarski, RN (planner/reviewer)	N/A	Nothing to disclose
AKH Inc Staff and Planners	N/A	Nothing to disclose
Association of Women in Rheumatology Staff and Planners	N/A	Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.		

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.